- |||||||||| Ciprol (ciprofibrate) / Sanofi, Cetaxin (ciprofibrat) / AC Farma
Aging and metabolic pathways in lung fibrosis () - Feb 20, 2024 - Abstract #ERSLSC2024ERS_LSC_63;
2. Is mitochondrial homeostasis primordial for epithelial lung progenitor function and tissue repair?
- |||||||||| Ergonex (ergotamine/caffeine) / AC Farma
Journal: Interdigitation of lipids for vesosomal formulation of ergotamine tartrate with caffeine: A futuristic trend of intranasal route. (Pubmed Central) - Jan 2, 2024
Objective: This research work aimed to form vesosomes using combination of two drugs ergotamine and caffeine for synergistic activity when given intranasally resulting in faster absorption, steric stability and controlled release.Significance: The multicompartment vesicles viz., vesosomes of ergotamine tartrate proved to increase absorption of drugs post-intranasal administration, bypassing the blood-brain barrier via the olfactory pathway The phospholipids like soya lecithin, cholesterol and dipalmitoyl phosphatidylcholine were used to form a multicompartment structure called vesosomes using ethanol-induced interdigitation of lipids as the preparation method. The formulation showed low particle size of 315.48?
- |||||||||| Ciprol (ciprofibrate) / Sanofi, Cetaxin (ciprofibrat) / AC Farma
Journal: Electrochemical N-Aroylation of Sulfoximines using Benzoyl Hydrazines with H2 Generation. (Pubmed Central) - Nov 22, 2023
The strategy is applied to late-stage sulfoximidation of L-menthol, (-)-borneol, D-glucose, vitamin-E derivatives, and marketed drugs such as probenecid, ibuprofen, flurbiprofen, ciprofibrate, and sulindac. In addition, the present methodology is mild, high functional group tolerance with broad substrate scope and scalable.
- |||||||||| Ergonex (ergotamine/caffeine) / AC Farma
Journal: Potentially Inappropriate Use of Opioids in the Management of Migraine in Colombia. (Pubmed Central) - Sep 28, 2023
The frequent use of opioids in the management of migraines is potentially inappropriate and can lead to problems of tolerance, abuse and dependence. This combined with the low prescription of triptans, offers an opportunity for improvements in medical practice.
- |||||||||| Ergonex (ergotamine/caffeine) / AC Farma
Journal: Use of 3D applicator for intranasal microneedle arrays for combinational therapy in migraine. (Pubmed Central) - Mar 20, 2023
The novel 3D applicator effectively delivered the microneedle array into the nasal cavity for systemic action. Therefore, the fabricated rapid dissolving microneedles combining two drugs ergotamine and caffeine with use of 3D applicator proved to be a coherent technique for intranasal delivery of ergotamine in the treatment of migraine.
- |||||||||| Ergonex (ergotamine/caffeine) / AC Farma
Journal: Self-Assembled Lipid Polymer Hybrid Nanoparticles Using Combinational Drugs for Migraine Via Intranasal Route. (Pubmed Central) - Dec 18, 2022
Histopathological investigations and serotonin toxicity studies in animals confirmed the safe and non-toxic nature of the formulation while the acetic acid writhing test proved the anti-hyperalgesic activity. The PEGylated lipid polymer hybrid nanoparticles of ergotamine and caffeine showed synergistic activity with efficacious higher anti-migraine potential.
- |||||||||| Ergonex (ergotamine/caffeine) / AC Farma
Journal: 2022 Taiwan Guidelines for Acute Treatment of Migraine. (Pubmed Central) - Sep 30, 2022
Evidence supporting the use of intravenous tramadol or morphine is insufficient; therefore, their use is not recommended...For moderate to severe attacks, oral or nasal spray triptans and ergotamine/caffeine compounds are recommended and should be administered in the early stage of migraine attacks...To prevent medication overuse headache, the use of acute treatment should be limited to a maximum of 2 days per week. Key words: acute migraine treatment, evidence-based medicine, treatment guidelines, triptans, ergotamine, neuromodulation.
- |||||||||| Ergonex (ergotamine/caffeine) / AC Farma
PK/PD data, Journal: Tracing the influence of caffeine on the pharmacokinetic parameters of three headache relieving pharmaceuticals applying synchronous fluorescence spectroscopy. (Pubmed Central) - Aug 12, 2022
A simple, sensitive, and selective first derivative synchronous fluorimetric method was developed and optimized to track the influence of caffeine content in beverages on the pharmacokinetic parameters of three pharmaceuticals used in relieving headache namely, aspirin (ASP), ibuprofen (IBU), and ergotamine tartrate (ERG)...Moreover, the developed bioanalytical method was subjected to full validation to avoid interferences emerging from biological matrices. The greenness of the proposed method was assessed according to the Analytical Eco-Scale and proved to be excellent green carrying a score of 98%.
- |||||||||| albumin-bound paclitaxel / Generic mfg.
Review, Journal: Nab-Paclitaxel related cystoid macular edema. (Pubmed Central) - Jul 23, 2022
When discontinuation of treatment is not possible due to the systemic conditions of patients, effective alternative therapeutic modalities are topical dorzolamide or steroidal treatment. Given the higher complication hazards of intravitreal therapy topical treatment should be preferred owing to comparable efficacy.
- |||||||||| Leflumide (leflunimide) / AC Farma
Journal: Research progress of BK virus and systemic lupus erythematosus. (Pubmed Central) - Apr 8, 2022
Some immunosuppressive drugs, like leflumide and hydroxychloroquine, may show a protective effect. BKV infection plays a role in the occurrence and development of SLE, and its significance deserves further exploration.
- |||||||||| Ciprol (ciprofibrate) / Sanofi, Cetaxin (ciprofibrat) / AC Farma, Visken (pindolol) / Novartis
Biomarker, Journal: Precision medicine for mood disorders: objective assessment, risk prediction, pharmacogenomics, and repurposed drugs. (Pubmed Central) - Jan 27, 2022
Finally, we provide an example of how a report to doctors would look for a patient with depression, based on the panel of top biomarkers (12 for depression and bipolar, one for mania), with an objective depression score, risk for future depression, and risk for bipolar switching, as well as personalized lists of targeted prioritized existing psychiatric medications and new potential medications. Overall, our studies provide objective assessments, targeted therapeutics, and monitoring of response to treatment, that enable precision medicine for mood disorders.
- |||||||||| Ergonex (ergotamine/caffeine) / AC Farma
Clinical, Review, Journal: The effects of caffeine in adults with neurogenic orthostatic hypotension: a systematic review. (Pubmed Central) - Nov 29, 2021
Overall, our studies provide objective assessments, targeted therapeutics, and monitoring of response to treatment, that enable precision medicine for mood disorders. Caffeine should only be considered as a treatment for adults with neurogenic orthostatic hypotension when evidence-based treatments have been exhausted.
- |||||||||| Ciprol (ciprofibrate) / Sanofi, Cetaxin (ciprofibrat) / AC Farma
Journal: Ciprofibrate-Loaded Nanoparticles Prepared by Nanoprecipitation: Synthesis, Characterization, and Drug Release. (Pubmed Central) - Sep 29, 2021
For Pluronic nanoparticles, we scanned different conditions for the CIP loading, and its encapsulation efficiency was reduced while the drug content increased in the nanoprecipitation protocol. We also performed in vitro release experiments; results demonstrate that probe release is driven by Fickian diffusion for the Pluronic NPs and a zero-order model for PEO-b-PCL NPs.
- |||||||||| Reyvow (lasmiditan) / Eli Lilly, Ergonex (ergotamine/caffeine) / AC Farma
Clinical, Retrospective data, Review, Journal: Acute Treatments for Episodic Migraine in Adults: A Systematic Review and Meta-analysis. (Pubmed Central) - Jul 7, 2021
Use of triptans, nonsteroidal anti-inflammatory drugs, acetaminophen, dihydroergotamine, calcitonin gene-related peptide antagonists, lasmiditan, and some nonpharmacologic treatments was associated with improved pain and function. The evidence for many other interventions, including opioids, was limited.
- |||||||||| Ciprol (ciprofibrate) / Sanofi, Cetaxin (ciprofibrat) / AC Farma
Journal: A prospective mechanism and source of cholesterol uptake by Plasmodium falciparum-infected erythrocytes co-cultured with HepG2 cells. (Pubmed Central) - Jun 22, 2021
Ezetimibe is known to inhibit cholesterol absorption by blocking the activity of Niemann-Pick C1 like 1 (NPC1L1) protein, and simvastatin is known to enhance NPC1L1 expression in the human body's small intestine. Collectively, our results support the possibility that cholesterol import by P. falciparum involves hepatocytes, and cholesterol uptake into the parasite occurs via NPC1L1 protein or an NPC1L1 homolog during the erythrocytic stages of the P. falciparum lifecycle.
- |||||||||| Ergonex (ergotamine/caffeine) / AC Farma
[VIRTUAL] Overt ergotism due to overuse of ergotamine-caffeine () - Jun 4, 2021 - Abstract #AHS2021AHS_166;
ergotamine exerts effects on multiple neurotransmitter pathways including norepinephrine and dopamine that can result in vasoconstriction and nausea/vomiting, respectively. The use of ergotamine is recommended only to a subset of patients given its significant side effect profile.
- |||||||||| Leflumide (leflunimide) / AC Farma
Journal: Drug-induced chronic cough and the possible mechanism of action. (Pubmed Central) - Apr 28, 2021
we should be alert to the possibility of drug-induced chronic cough after excluding CVA, UACS, EB and other common causes of chronic cough. This article reviews the relevant drugs that may cause cough and their possible mechanisms of action.
- |||||||||| Ciprol (ciprofibrate) / Sanofi, Cetaxin (ciprofibrat) / AC Farma
[VIRTUAL] RARE XANTHOMATOSIS IN HYPERLIPIDEMIA CASE (eAbstract site) - Feb 17, 2021 - Abstract #ACC2021ACC_8101;
This article reviews the relevant drugs that may cause cough and their possible mechanisms of action. The most significant aspect was the unusual extensive xanthomatosis, rarely seen in phenotype IIb, what underlines the necessity of correct diagnosis and handling of such cases precociously by specialized services, so therapy can be effective and clinical complications are reduced.
- |||||||||| Ciprol (ciprofibrate) / Sanofi, Cetaxin (ciprofibrat) / AC Farma
Trial completion: Ciprofibrate and Pre-diabetes (clinicaltrials.gov) - Jan 8, 2021
P3, N=11, Completed,
Validation parameters were checked according to International Conference of Harmonization guidelines to achieve the international requirements for quality control analysis of the proposed drugs. Recruiting --> Completed
- |||||||||| Xifaxan (rifaximin) / Alfa Wassermann, Bausch Health, Norgine, ASKA Pharma
Clinical, Review, Journal: Efficacy of rifaximin in the different clinical scenarios of hepatic encephalopathy. (Pubmed Central) - Jan 1, 2021
Even though many of them have been shown to be effective to greater or lesser degrees, it is important to understand the differences between them, so that every patient receives individualized treatment and the best option is chosen, in accordance with the different clinical scenarios. Thus, the aim of the present study was to analyze the evidence on the advantages and disadvantages of the individual or combined use of the 3 main treatments for hepatic encephalopathy, specifically taking into consideration their different degrees of efficacy, their impact on quality of life, prophylaxis, and cost reduction.
- |||||||||| Ciprol (ciprofibrate) / Sanofi, Cetaxin (ciprofibrat) / AC Farma
Preclinical, Journal: Ciprofibrate attenuates airway remodeling in cigarette smoke-exposed rats. (Pubmed Central) - Jun 8, 2020
Ciprofibrate also significantly reduced IL-1β, IL-12p70, IL-17A and IL-18 expression, which are related to airway remodeling, in the sera of CS-exposed rats. These findings indicate that ciprofibrate could attenuate airway remodeling in CS-exposed rats.
- |||||||||| clotrimazole / Generic mfg.
Preclinical, Journal: Acetoacetate Enhances Oxidative Metabolism and Response to Toxicants of Cultured Kidney Cells. (Pubmed Central) - Feb 28, 2020
There was a marked increase in uncoupled respiration in the presence of diclofenac, while clotrimazole and ciprofibrate significantly decreased respiration in the acetoacetate. The results indicate that acetoacetate complemented media can alter cellular metabolism and increase sensitization to toxicants.
- |||||||||| Ciprol (ciprofibrate) / Sanofi, Cetaxin (ciprofibrat) / AC Farma
Enrollment open: Ciprofibrate and Pre-diabetes (clinicaltrials.gov) - Nov 28, 2018
P3, N=12, Recruiting,
The results indicate that acetoacetate complemented media can alter cellular metabolism and increase sensitization to toxicants. Not yet recruiting --> Recruiting
- |||||||||| Ciprol (ciprofibrate) / Sanofi, Cetaxin (ciprofibrat) / AC Farma
New P3 trial: Ciprofibrate and Pre-diabetes (clinicaltrials.gov) - Sep 10, 2018
P3, N=12, Not yet recruiting,
- |||||||||| Ergonex (ergotamine/caffeine) / AC Farma
Phase classification, Enrollment change: Treatment of Orthostatic Hypotension in Autonomic Failure (clinicaltrials.gov) - Jan 18, 2017
P1, N=389, Completed,
Not yet recruiting --> Recruiting Phase classification: P3 --> P1 | N=80 --> 389
- |||||||||| Ergonex (ergotamine/caffeine) / AC Farma
Trial completion, Enrollment change, Trial primary completion date: Treatment of Orthostatic Hypotension in Autonomic Failure (clinicaltrials.gov) - Jan 17, 2017
P3, N=80, Completed,
Phase classification: P3 --> P1 | N=80 --> 389 Recruiting --> Completed | N=500 --> 80 | Trial primary completion date: Apr 2017 --> Jan 2017
- |||||||||| Ergonex (ergotamine/caffeine) / AC Farma
Trial primary completion date: Treatment of Orthostatic Hypotension in Autonomic Failure (clinicaltrials.gov) - Apr 28, 2016
P3, N=500, Recruiting,
Recruiting --> Completed | N=500 --> 80 | Trial primary completion date: Apr 2017 --> Jan 2017 Trial primary completion date: Apr 2016 --> Apr 2017
|
